¡¡¡¡Soy Doctor en Medicina!!!! 👨🏼‍🎓

No sé si sois conscientes de que la Fiscalía Europea tiene abierta una investigación contra el Gobierno por FRAUDE con los fondos 'Next Gen' en el mantenimiento de las vías Madrid-Sevilla. Adif fue la segunda empresa de toda Europa que más dinero recibió, 5.825 millones. Tanto la Comisión Europea como el Tribunal de Cuentas desvelaron hace poco que Sánchez estaba ocultando a dónde había ido todo ese dinero. PODEMOS ESTAR ANTE EL MAYOR CASO DE CORRUPCIÓN DE LA HISTORIA.

La portada.

Óscar Puente debe dimitir HOY mismo Pásalo 🔄

Making sense of surrogate endpoints in Oncology, now at the YO Brunch session, by Florian Lordick #ESMO26 #ESMOAmbassadors @myESMO

Young Oncologists sessions today at #ESMO26 *9:00-10:00 clinical case discussion (TOLEDO) *10:30-11:15: Brunch 2 (SANTANDER) *15:00-16:00: medical students session (TOLEDO) @myESMO

Today at #ESMO26 ICI may still have a role in HR+/HER2- MBC, although still many uncertainties: -what is the best biomarker beyond PDL1? -what population? -could intrinsic subtypes (luminal vs non-luminal) add some light? #ESMOAmbassadors @myESMO

At 15y analyses, extended ET did not show an OS benefit. Now both adjuvant abema and ribo have positive OS results. Do you think there is still a role for extending ET after adjuvant CDK4/6i? #ESMO26 #ESMOAmbassadors @myESMO

Great presentation by @VivekSubbiah at the ESMO Young Oncologist Symposium, led by @Rodrosb. Inspiring insights and a great discussion!

📣Join us today for the YO Brunch session 1: Digital technologies in YO daily life 📱💻 Starting at 10:30, Santander auditorium Lunch box included!

Proffered paper BC session 2 at #ESMO26: Great to see EVE + ET as comparator arm in post-CDK4/6i RCT The ph2 FOURLIGHT-01 trial: Atirmociclib (selective CDK4i) + fulvestrant shows a clinically meaningful PFS of 9,4 months vs 6,6 (fulve / exe + eve) #ESMOAmbassadors @myESMO

Thank you to the @myESMO #ESMO26 #YOC for the invitation to you for the #YOMentorshipSession We discussed #ScienceCommunication and #MedicalJournalism, within many other topics!!! Ver active and participating group of YOCs! Thank you all 🙏 #ESMOAmbassadors

#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by @breastDoktor #InsightsbyESMO ➡️ ow.ly/ZBwi50ZZXLm

📣 Presented today at #ESMO26 with concomitant publication at @ESMO_Open Results from the PROCURE Project, assessing genetic predisposition to ILD in patients treated with TDXd

Now at #ESMO26 new phase 3 evidence for novel antiHER2 ADCs in HER2low MBC. The question is: is chemotherapy still a valid comparator in this setting where TDXd has become a new standard? #ESMOAmbassadors @myESMO

#ESMO26 kicks off in Madrid 🇪🇸 today! As an @myESMO YOC member, I'm excited to share our Young Oncologists Programme! 🎓 Mentorship 🩺 Clinical cases 🔬 Research & career development 📅 23–26 Oct Join us and connect with the next generation of oncology! 🌍 #ESMOYOC

Attending #ESMO26? 📱Download the ESMO Events App to browse the programme, save your must-attend sessions and create your personalised agenda before you arrive. A simple step to help you make the most of your congress experience from day one. 🔗 ow.ly/nbMX50ZZXgz

New at #ESMO26: the ESMO Principles for Humanising Scientific Reporting. Designed to strengthen the communication of oncology research while maintaining scientific rigour and patient relevance. 🔗 ow.ly/WzeJ50ZZIqH

📰 @ESMO_Open publica el paper 'Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE project', un estudio multicéntrico presentado por el Dr. @Rodrosb en la Plenaria de #SEOM26 🔗 sciencedirect.com/science/ar…